Department of Cardiology, Erasmus University Medical Centre; 3015 Rotterdam; The Netherlands.
Expert Rev Cardiovasc Ther. 2023 Feb;21(2):97-109. doi: 10.1080/14779072.2023.2177635. Epub 2023 Feb 15.
Heart failure (HF) is considered as a chronic long-term and lethal disease and will continue to be a major public health problem. Studying (circulating) biomarkers is a promising field of research and could be the first step toward HF tailored prognostic strategies as well as understanding the response to HF drugs in CHF patients.
In literature, there has been considerable research on elevated biomarker levels that are related to a poor prognosis for HF. Since biomarker levels change over time, it is important to study serial (repeated) biomarker measurements which may help us better understand the dynamic course of HF illness. However, the majority of research focuses predominantly on baseline values of biomarkers. Additionally, remote monitoring devices, like sensors, can be used to link hemodynamic information to freshen biomarker data in order to further ameliorate the management of HF.
Novel biomarkers and additional scientific insights with hemodynamic feedback strongly aid in the prognostication and risk prediction of chronic HF.
心力衰竭(HF)被认为是一种慢性的、长期的致命疾病,它将继续成为一个主要的公共卫生问题。研究(循环)生物标志物是一个很有前途的研究领域,它可能是制定针对心力衰竭的预后策略以及了解心力衰竭药物在充血性心力衰竭患者中的反应的第一步。
在文献中,已经有相当多的研究关注与心力衰竭预后不良相关的升高的生物标志物水平。由于生物标志物水平随时间而变化,因此研究连续(重复)的生物标志物测量非常重要,这可能有助于我们更好地了解心力衰竭疾病的动态过程。然而,大多数研究主要集中在生物标志物的基线值上。此外,远程监测设备,如传感器,可用于将血液动力学信息与生物标志物数据联系起来,以进一步改善心力衰竭的管理。
新型生物标志物和具有血液动力学反馈的新科学见解有助于对慢性心力衰竭进行预后和风险预测。